moderately obese subjects in our study was identical to that reported in a recent meta-analysis on long-term pharmacotherapy for obesity. In response to Ornish’s letter: the low-carbohydrate diet was based on Atkins’s book, although we encouraged the study participants to consume a variety of protein and fat sources to maintain successful long-term adherence. We specifically reported on retention in detail and noted that adherence was higher in this trial than in any other trial of a similar length that we know of. The setting and methods we used to maximize adherence rates permitted a robust test of the three dietary strategies, as assessed by weight loss and established measurements of lipids, glycemic control, and hepatic and inflammatory biomarkers. As noted by Manzoni and colleagues, we did not assess cost-effectiveness. However, we believe that cost-effective interventions can be implemented in the workplace, with the use of group meetings and by working with food-service providers.

Several readers have informed us that our online Supplementary Appendix was incomplete. We have updated the appendix to provide more complete information.

Iris Shai, R.D., Ph.D.
Ben-Gurion University
Beer-Sheva 84105, Israel
irish@bgu.ac.il
Yaakov Henkin, M.D.
Soroka University Medical Center
Beer-Sheva 84101, Israel
Meir J. Stampfer, M.D., Dr.P.H.
Harvard Medical School
Boston, MA 02115

TO THE EDITOR: In a randomized study of the effect of tibolone on fracture rates among postmenopausal women between the ages of 60 and 85 years, Cummings et al. (Aug. 14 issue) report that tibolone significantly reduced the risk of invasive breast cancer. The authors also report that this finding contradicted the results of the observational Million Women Study, which showed that the use of tibolone for up to 5 years was associated with an increased risk of breast cancer. In analyses combining clinical-trial and observational-study cohorts, the Women’s Health Initiative (WHI) showed that a decreased risk of breast cancer was associated with estrogen therapy only if estrogen was given several years after menopause and not when it was begun soon thereafter.

Since women in nontrial settings usually begin such hormonal therapy shortly after the onset of menopause, the gap time after menopause provides a potential effect modifier, suggesting caution in extrapolating findings to women closer to menopause. In the WHI randomized trial, estrogen plus progesterin increased the risk of breast cancer that was diagnosed at an advanced stage, suggesting diagnostic delay with fewer cancers in the hormone group through the first 3 years of follow-up. The current tibolone trial was reported after a median of 34 months and without information on tumor stage. Although tibolone does not increase breast density, as does combined hormone therapy, could diagnostic delay account for some of the breast-cancer findings?

Rowan T. Chlebowski, M.D., Ph.D.
LABioMed
Torrance, CA 90502
rchlebowski@gmail.com
Ross Prentice, Ph.D.
Fred Hutchinson Cancer Research Center
Seattle, WA 98109

Dr. Chlebowski reports receiving consulting fees from AstraZeneca, Novartis, Eli Lilly, and Wyeth and grant support from Eli Lilly, Organon, and Amgen. No other potential conflict of interest relevant to this letter was reported.


TO THE EDITOR: With respect to the study by Cummings et al, we raise two issues: First, among the risk factors for stroke, the authors did not include the presence of high triglyceride levels and low levels of high-density lipoprotein (HDL) cholesterol, which have been shown to be related to ischemic cerebrovascular events.1,2 Were these values similar in the two study groups at baseline? Were they modified by the administration of tibolone? Second, regarding gynecologic outcomes, patients who were treated with tibolone had a significantly higher incidence of mild cervical dysplasia on cytologic analysis than did those receiving placebo (7.6% vs. 3.2%, P = 0.009), but there were no differences between the groups in the incidence of moderate-to-severe dysplasia. Several studies have noted a synergistic role of sex hormones with human papillomavirus (HPV) infection in facilitating cervical carcinogenesis by inducing squamous metaplasia and by modifying the local immune microenvironment.3,4 This carcinogenic process requires several years. In the study by Cummings et al., the median duration of treatment was 34 months. We wonder whether in this period of time the possible HPV hyperactivation induced by tibolone could have caused mild dysplasia, whereas higher-grade dysplasia would have required a longer exposure.

Maurizio Serati, M.D.
Stefano Uccella, M.D.
PierFrancesco Bolis, M.D.
University of Insubria
21100 Varese, Italy
mauserati@hotmail.com


THE AUTHORS REPLY: Chlebowski and Prentice wonder whether a delay in diagnosis might account for some of the reduction in the risk of breast cancer that we observed among patients receiving tibolone. There was no significant difference between the groups in the use of mammography. As Chlebowski and Prentice note, tibolone does not appear to increase breast density, and there is no other reason why tumors would be more difficult to detect in women taking tibolone. Although data about the stage of cancers at diagnosis were not available in the trial, it seems unlikely that diagnostic delay could account for a meaningful part of the 68% decreased risk of invasive breast cancer.

Serati and colleagues ask whether changes in cholesterol and triglycerides might account for the increased risk of stroke we observed in patients receiving tibolone. We did not measure lipid concentrations in our trial, precluding an analysis of how much of the increased risk of stroke might have been due to changes in lipids. However, in previous placebo-controlled trials,1 2 years of treatment with 1.25 mg or 2.5 mg of tibolone daily resulted in decreases in HDL cholesterol levels of 14% and 22%, decreases in triglyceride levels of 21% and 23%, and decreases in lipoprotein(a) levels of 40% and 51%, respectively, whereas there were no significant changes in levels of low-density lipoprotein cholesterol (an increase of 3% and a decrease of 2%, respectively). We have no data from our trial and know of no other studies that address the speculation raised by Serati et al. as to whether tibolone might activate HPV.

Steven R. Cummings, M.D.
San Francisco Coordinating Center
San Francisco, CA 94107

Victoria Statthopolous, Ph.D.
Organon
Roseland, NJ 07068